Patents by Inventor Farshad Guirakhoo

Farshad Guirakhoo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11857611
    Abstract: The compositions and methods are described for generating an immune response to a Plasmodium antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to malaria by expressing the Plasmodium antigen in the subject to which the MVA vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat malaria.
    Type: Grant
    Filed: April 21, 2022
    Date of Patent: January 2, 2024
    Assignee: Geovax, Inc.
    Inventors: Farshad Guirakhoo, Arban Domi, Nathanael Paul McCurley
  • Patent number: 11801299
    Abstract: The compositions and methods are described for generating an immune response to a hepatitis B virus. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a hepatitis B virus, in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat an infection caused by hepatitis B virus.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: October 31, 2023
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: Farshad Guirakhoo, Arban Domi, Nathanael P. McCurley, Rahul Basu, Ming Luo
  • Publication number: 20230256088
    Abstract: The compositions and methods are described for generating an immune response to a tumor associated antigen such as MUC-1. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to MUC-1 in the subject to which the vector is administered and boosting the immune response by administering a MUC-1 peptide. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat neoplasms and associated diseases.
    Type: Application
    Filed: September 22, 2022
    Publication date: August 17, 2023
    Applicant: GeoVax, Inc.
    Inventor: Farshad Guirakhoo
  • Publication number: 20230181725
    Abstract: Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.
    Type: Application
    Filed: November 22, 2022
    Publication date: June 15, 2023
    Inventors: Klaus Orlinger, Karen Lingnau, Thomas Monath, Farshad Guirakhoo, Gerhard Fuhrmann, Katherine Cohen, Vera Baumgartl-Strasser, Andreas Aspöck, Manuela Kainer, Bernhard Brim, Bettina Kiefmann, Elizabeth Watson, Mario Aistleithner, Katharina Bayer, Elsa Mühlbacher
  • Patent number: 11638750
    Abstract: The compositions and methods are described for generating an immune response to a flavivirus such as Zika virus. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a member of genus Flavivirus (such as a member of species Zika virus), in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat an infection caused by Flavivirus.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: May 2, 2023
    Assignee: Geovax, Inc.
    Inventors: Farshad Guirakhoo, Arban Domi, Nathanael Paul McCurley
  • Publication number: 20230040403
    Abstract: The compositions and methods are described for generating an immune response to an antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens as a fusion product with a viral glycoprotein and matrix protein for generating a protective immune response to a subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat diseases.
    Type: Application
    Filed: July 29, 2022
    Publication date: February 9, 2023
    Applicant: GeoVax, Inc.
    Inventors: Harriet Robinson, Arban Domi, Michael Hellerstein, Farshad Guirakhoo, Nathanael Paul McCurley
  • Patent number: 11554169
    Abstract: Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: January 17, 2023
    Assignee: Hookipa Biotech GmbH
    Inventors: Klaus Orlinger, Karen Lingnau, Thomas Monath, Farshad Guirakhoo, Gerhard Fuhrmann, Katherine Cohen, Vera Baumgartl-Strasser, Andreas Aspöck, Manuela Kainer, Bernhard Brim, Bettina Kiefmann, Elizabeth Watson, Mario Aistleithner, Katharina Bayer, Elsa Mühlbacher
  • Publication number: 20220396810
    Abstract: Provided herein are recombinant modified vaccinia Ankara (rMVA) viral vectors comprising heterologous nucleic acid inserts encoding one or more SARS-CoV2 proteins, peptides, or fragments thereof, operably linked to a promoter compatible with poxvirus expression systems that, upon expression, are capable of inducing protective immunity. The compositions can be used in a priming vaccination strategy or in a prime/boost vaccination strategy to provide immunity to SARS-CoV2 and variants thereof.
    Type: Application
    Filed: August 15, 2022
    Publication date: December 15, 2022
    Applicant: GeoVax, Inc.
    Inventors: Mary Jo Hauser, Arban Domi, Farshad Guirakhoo
  • Publication number: 20220313808
    Abstract: The compositions and methods are described for generating an immune response to a Plasmodium antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to malaria by expressing the Plasmodium antigen in the subject to which the MVA vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat malaria.
    Type: Application
    Filed: April 21, 2022
    Publication date: October 6, 2022
    Applicant: Geovax, Inc
    Inventors: Farshad Guirakhoo, Arban Domi, Nathanael Paul McCurley
  • Patent number: 11413341
    Abstract: The compositions and methods are described for generating an immune response to an antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens as a fusion product with a viral glycoprotein and matrix protein for generating a protective immune response to a subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat diseases.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: August 16, 2022
    Assignee: Geovax, Inc.
    Inventors: Harriet Robinson, Arban Domi, Michael Hellerstein, Farshad Guirakhoo, Nathanael Paul McCurley
  • Publication number: 20220160853
    Abstract: The compositions and methods are described for generating an immune response to a tumor associated antigen (TAA) such as MUC-1, survivin, cyclin B1, HBV, or HPV. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to the tumor associated antigen in the subject to which the vector is administered and optionally, boosting the immune response by administering a tumor associated antigen. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat neoplasms and associated diseases.
    Type: Application
    Filed: December 3, 2021
    Publication date: May 26, 2022
    Applicant: GeoVax, Inc.
    Inventors: Farshad Guirakhoo, Arban Domi
  • Patent number: 11311612
    Abstract: The compositions and methods are described for generating an immune response to a Plasmodium antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to malaria by expressing the Plasmodium antigen in the subject to which the MVA vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat malaria.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: April 26, 2022
    Assignee: Geovax, Inc.
    Inventors: Farshad Guirakhoo, Arban Domi, Nathanael Paul McCurley
  • Publication number: 20220118082
    Abstract: The compositions and methods are described for generating an immune response to a hepatitis B virus. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a hepatitis B virus, in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat an infection caused by hepatitis B virus.
    Type: Application
    Filed: July 6, 2021
    Publication date: April 21, 2022
    Applicants: GeoVax, Inc., The Georgia State University Research Foundation
    Inventors: Farshad Guirakhoo, Arban Domi, Nathanael P. McCurley, Rahul Basu, Ming Lo
  • Patent number: 11278607
    Abstract: The compositions and methods are described for generating an immune response to a tumor associated antigen such as MUC1. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a neoplasm expressing the tumor associated antigen in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat neoplasms and associated diseases.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: March 22, 2022
    Assignee: Geovax, Inc.
    Inventors: Harriet Robinson, Arban Domi, Michael Hellerstein, Farshad Guirakhoo, Nathanael Paul McCurley
  • Publication number: 20210220469
    Abstract: The compositions and methods are described for generating an immune response to a tumor associated antigen such as MUC-1. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to MUC-1 in the subject to which the vector is administered and boosting the immune response by administering a MUC-1 peptide. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat neoplasms and associated diseases.
    Type: Application
    Filed: August 24, 2018
    Publication date: July 22, 2021
    Inventor: Farshad Guirakhoo
  • Patent number: 11052148
    Abstract: The compositions and methods are described for generating an immune response to a hepatitis B virus. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a hepatitis B virus, in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat an infection caused by hepatitis B virus.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: July 6, 2021
    Assignees: Geo Vax, Inc., The Georgia State University Research Foundation
    Inventors: Farshad Guirakhoo, Arban Domi, Nathanael P. McCurley, Rahul Basu, Ming Luo
  • Publication number: 20210100891
    Abstract: The compositions and methods are described for generating an immune response to a Flavivirus such as Zika virus. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a member of genus Flavivirus (such as a member of species Zika virus), in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat an infection caused by Flavivirus.
    Type: Application
    Filed: August 24, 2020
    Publication date: April 8, 2021
    Inventors: Farshad Guirakhoo, Arban Domi, Nathanael Paul McCurley
  • Publication number: 20200289633
    Abstract: The compositions and methods are described for generating an immune response to an antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens as a fusion product with a viral glycoprotein and matrix protein for generating a protective immune response to a subject to which the vector is administered.
    Type: Application
    Filed: February 20, 2020
    Publication date: September 17, 2020
    Applicant: GeoVax, Inc.
    Inventors: Harriet Robinson, Arban Domi, Michael Hellerstein, Farshad Guirakhoo, Nathanael Paul McCurley
  • Publication number: 20200282036
    Abstract: The compositions and methods are described for generating an immune response to a Plasmodium antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to malaria by expressing the Plasmodium antigen in the subject to which the MVA vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat malaria.
    Type: Application
    Filed: September 18, 2018
    Publication date: September 10, 2020
    Inventors: Farshad Guirakhoo, Arban Domi, Nathanael Paul McCurley
  • Publication number: 20200171141
    Abstract: Compositions and methods are described for generating an immune response to an arenavirus. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a member of genus Arenavirus (such as a member of species Lassa virus) in the subject to which the vector is administered. The compositions and methods of the present invention may be used to prevent and/or treat an infection caused by arenavirus.
    Type: Application
    Filed: July 18, 2018
    Publication date: June 4, 2020
    Inventors: Farshad Guirakhoo, Arban Domi